Category: ACN Newswire

香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 近日，标普全球（S&P Global）在其发布的最新简报中明确表示，预计国泰海通集团下属公司国泰君安国际控股有限公司（“国泰君安国际”、“公司”，股份代号：1788.HK）及其直接控股公司国泰海通金融控股有限公司（“国泰海通金控”）作为母公司国泰海通证券股份有限公司（“国泰海通”）核心子公司，将继续在集团国际化战略中发挥关键作用。标普全球在简报中指出，国泰君安国际与母公司在投资银行及财富管理领域的业务协同效应显著，进一步强化了其在集团内部的重要性。国际化发展为国泰海通的核心战略重点之一，国泰君安国际将继续在集团加强全球布局的过程中扮演关键角色。2025年，国泰君安国际及国泰海通金控分别实现利润增长284%及85%，分别占国泰海通证券当年净利润约3%及8%。这一强劲的财务表现，有力印证了公司对集团整体业务发展的贡献。标普全球预期，国泰君安国际未来两年仍将作为集团核心子公司之一，持续获得母公司支持，其发行人信用评级及“稳定”展望将与母公司保持同步。标普全球认为，公司可获得母公司稳定、及时的支持，包括在必要时通过国泰海通间接受益于上海政府的资源。这份简报充分反应了公司的现况及对未来发展的预期。国泰君安国际将坚定不移地配合集团国际化战略，持续提升自身的专业能力及与集团的业务协同效率，为国泰海通集团成为具备国际竞争力与市场引领力的一流投资银行作出贡献。注：本文内容基于标普全球评级于2026年5月5日发布的独立观点文件（Tear Sheet：Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.），该文件不构成评级行动。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK），是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高质量、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予“Baa2”及“BBB+”长期发行人评级，MSCI ESG“AAA”评级, Wind ESG“A”评级及商道融绿ESG“A”评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的信息请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.Over 90 global leaders share insight into healthcare innovation development and AI applicationsThe sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in disease management.”Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in areas such as longevity.The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”Over 400 deal‑making sessions drive investment and business matchingBeyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”Building bridges for “go global” and other cross‑border healthcare collaborationsBuilding on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hubThe Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.” Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.Photo download: https://bit.ly/4nokRfTThe sixth Asia Summit on Global Health was attended by some 3,000 participants from 43 countries and regions.Dr Alex Mihailidis, Associate Vice President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE WELL, attended and shared his insight.In the session Transforming Healthcare through Digital Health & AI Innovations, Natasha Chhatrapati, Senior Director, Business Transformation Lead for International at Pfizer Inc, engaged with fellow panellists to examine the practical implementation and the latest breakthroughs in AI within the healthcare sector.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises brought together experts in regulation, clinical trials, IP protection and distribution to share practical insights on international expansion.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.The ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together around 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies.HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises to “go global” via Hong Kong and target the Singapore and ASEAN markets.The 17th Hong Kong International Medical and Healthcare Fair attracted buyers from 61 countries and regions, with some 13,000 buyers visiting the fair for sourcing and procurement.The Hong Kong MedTech Association led some 20 companies to exhibit at the fair, drawing strong buyer interest and encouraging in‑depth business discussions.The Canada Pavilion brought together a number of companies to promote their medical equipment, technology application solutions and related services, attracting buyers to explore opportunities and engage in business discussions.Hong Kong Science and Technology Parks Corporation led over 30 innovation and technology companies to exhibit at the Fair, showcasing the strength of Hong Kong’s local medical innovation and R&D capabilities.Industry experts at the themed session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong” shared the latest market trends, fostering active exchanges among industry stakeholders.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enList of Product: https://www.hktdc.com/event/hkmedicalfair/en/product Media enquiriesYuan Tung Financial Relations:Jasmine ZhangTel: (852) 3428 3278Email: jzhang@yuantung.com.hkLouise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Noah QiuTel: (852) 2584 4575Email: noah.yl.qiu@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgSerena CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ORLANDO, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At SAP Sapphire in 2026, SAP SE (NYSE: SAP) introduced the Autonomous Enterprise to help enhance the world’s most critical business workflows, so that humans and AI work together to meet the accelerating demands of global business profitably, strategically and safely. “For the mission-critical processes of our customers,‘almost right’just isn’t good enough,” said Christian Klein, CEO of SAP SE,“By uniting SAP Business AI Platform with SAP Autonomous Suite, we anchor AI agents in the business processes, data and governance so they can deliver accurate, compliant and secure outcomes, unlocking new sources of revenue and meaningful cost savings.”The Autonomous Enterprise includes a unified AI platform for building, contextualizing and governing agents, an autonomous suite that executes core business operations and a new user experience that redefines how people work with enterprise software.Introducing SAP Business AI PlatformSAP Business AI Platform is a new foundation for building and deploying enterprise AI grounded in real business context. SAP Business AI Platform now unifies SAP Business Technology Platform, SAP Business Data Cloud and SAP Business AI into a single, governed environment.At its core is the SAP Knowledge Graph solution, which gives AI agents a structured map of business entities, processes and relationships across a customer’s SAP landscape. Joule Studio is SAP’s AI-first solution for building enterprise agents, applications and agentic workflows. Developers can build using the no-code, pro-code and AI frameworks of their choice on SAP-managed infrastructure that is secure, scalable and optimized for enterprise AI.Deploying SAP Autonomous Suite Across Every Business Function and IndustryBuilding on this foundation, SAP also introduced SAP Autonomous Suite, which enables SAP’s existing business applications with AI agents capable of running processes from start-to-finish.The suite will deploy more than 50 domain-specific Joule Assistants across finance, supply chain, procurement, human capital management and customer experience. These assistants will automate end-to-end processes by orchestrating a subset of over 200 specialized agents to execute precise tasks. For example, the new Autonomous Close Assistant can compress the financial close process from weeks to days by automating journal entries, reconciliation and error resolution across the entire process.SAP also launched Industry AI, expanding its deep industry portfolio through seven autonomous solutions that will enable start-to-finish industry processes and embed sector-specific process logic, data models and regulatory requirements. At SAP Sapphire, SAP showcased its work with European energy giant RWE to leverage Industry AI, helping reduce unplanned downtime across its offshore wind turbines. With SAP’s Autonomous Asset Management scenario, AI agents are designed to analyze data from thousands of past incidents, identify the likely root cause and generate pre-filled work orders with the right tools and proven fixes from other sites.Designing the Autonomous User ExperienceThe company also revealed Joule Work, redefining how users engage with SAP software. Instead of navigating individual applications and entering data across several screens, users will now interact primarily with Joule. By describing a desired business outcome, Joule will orchestrate the right combination of workflows, data and agents to get it done.Joule Work goes beyond conversation, proactively surfacing relevant insights and automating routine tasks behind the scenes so work moves forward even when humans aren’t actively steering it. It will be available on desktop, mobile and voice across SAP and non-SAP systems.Accelerating the Customer Journey Toward Autonomy with €100 Million InfusionSAP evolved its customer and partner programs to help accelerate the organization’s journey to the Autonomous Enterprise. To catalyze adoption, the company has launched a €100 million fund for SAP partners to help customers deploy SAP-built AI assistants and agents. The fund is also available to partners that extend or build new partner agents on the new SAP Business AI Platform using Joule Studio.SAP has enhanced its RISE with SAP and SAP GROW offerings to accelerate AI adoption. Both include access to the Joule Assistants portfolio; RISE with SAP customers will have three assistants activated within their first year, while SAP GROW customers receive full portfolio access at onboarding. SAP S/4HANA on-premises and SAP ERP Central Component (SAP ECC) customers are not excluded: those that commit to transitioning the majority of their current landscape to SAP Cloud ERP gain access to select AI scenarios, bridging the gap between their current landscape and their cloud destinationSAP also introduced new agent-led transformation tooling that can reduce ERP migration efforts by more than 35 percent, driving faster and more predictable projects by automating system analysis, code remediation, configuration and testing at scale.Lastly, SAP announced a full slate of strategic partnerships across each category:- Platform and suite partnerships include Anthropic, with Claude among the foundation models SAP’s AI platform will leverage to power Joule agents across HR, procurement and supply chain; Amazon Web Services, bringing zero-copy data integration between SAP Business Data Cloud and Amazon Athena; Google Cloud and Microsoft, enabling bidirectional agent-to-agent interoperability between Joule and external agent frameworks; Mistral AI and Cohere, delivering sovereign model options on SAP’s cloud infrastructure; n8n, providing visual AI workflow orchestration inside Joule Studio; NVIDIA, whose OpenShell provides the trusted secure runtime for Joule Studio; and Parloa, bringing AI agents into SAP Service Cloud to handle customer interactions with full access to business data and service processes.- Implementation partnerships include Palantir and Accenture, partnering on complex data migration scenarios, and Conduct for AI-powered cloud ERP migrations.Learn more in the SAP Sapphire 2026 Innovation News Guide.Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.Photo download: https://bit.ly/42zNb5hAbout SAPAs a global leader in enterprise applications and Business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com/hk.For more information, press only:Strategic Public Relations Group (SPRG)Andico TsuiEmail: andico.tsui@sprg.com.hkTel: 2114 4346 / 6902 3831 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Financial HighlightsFor the three months Ended 31 March 2026(HK$ million)20262025ChangeRevenue 1,115.61,071.9+ 4.1%Gross Profit402.1376.1+ 6.9%Gross Profit margin36.0%35.1%+ 0.9ppProfit attributable to owners of the Company122.4110.0+ 11.3%Net profit margin11.0%10.3%+ 0.7ppAdjusted EBITDA 209.0201.5+ 3.7%Earnings per share (HK cents)11.7310.54+ 11.3%HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its unaudited first quarter financial results for the three months ended 31 March 2026 (the “Reporting Period”).The Group reported revenue of HK$1,115.6 million for the Reporting Period, representing an increase of 4.1% from HK$1,071.9 million of the corresponding period of 2025. Gross profit increased by 6.9% year-on-year to HK$402.1 million, due to the continued implementation of cost efficiency initiatives. Gross profit margin increased by 0.9 percentage points to 36.0% from 35.1% of the corresponding period of 2025 mainly attributable to the increased sales volume of the core brands to absorb cost pressure. Profit attributable to owners of the Company notably increased by 11.3% year-on-year to HK$122.4 million, while Adjusted EBITDA grew by 3.7% year-on-year to HK$209.0 million.Revenue from Hong Kong and other regions operations increased moderately by 3.1% due to the stable performance of the noodles business, particularly the Group’s core brands of Cup Noodles and Demae Iccho. As for the Chinese Mainland operations, revenue increased by 4.6% due to the sales expansion in the inland areas and the appreciation of Renminbi to Hong Kong Dollars.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Building on the solid momentum established in 2025, the Group delivered another quarter of resilient growth, with steady performance across our key markets. Revenue and profitability improved year-on-year, supported by stable sales volumes. Our core noodles business continued to perform well across regions, while our premiumisation and diversification strategies gained further traction in the Chinese Mainland. With a balanced regional footprint and enhanced operational execution, the Group remains well positioned to deliver sustainable growth and long-term value for shareholders.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

丹麦比隆, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 在乐高基金会年度会议上，董事会选举阿格妮特·柯克·克里斯蒂安森担任董事会主席。作为乐高集团所有者柯克·克里斯蒂安森家族的第四代成员，她成为该基金会自1986年成立以来仅有的第五位主席。阿格妮特·柯克·克里斯蒂安森自2023年起担任乐高基金会副主席，此次接替其兄长托马斯·柯克·克里斯蒂安森出任主席，后者卸任后将担任副主席。除在乐高基金会的职务外，阿格妮特·柯克·克里斯蒂安森还担任家族控股及投资公司KIRKBI A/S的副主席，该公司持有乐高集团75%的股份。作为新任主席，阿格妮特·柯克·克里斯蒂安森强调了乐高基金会在为全球儿童创造更美好未来方面所发挥的作用：· “能够接任乐高基金会主席一职，并继续我们为儿童开展的重要工作，我深感荣幸。自40多年前成立以来，该基金会在我们家族中一直占据着非常特殊的地位。为儿童创造积极影响的深切责任感贯穿于我们家族的始终，我坚信每个孩子都应有机会茁壮成长。我为能为这一使命贡献力量并助力其传承而感到自豪。此次主席交接发生在阿格妮特接任非营利基金会“奥勒·柯克基金会”（Ole Kirk's Fond）主席一职的次年。随着这一交接，家族第四代成员正进一步拓展其参与范围，并致力于践行积极所有权。卸任主席托马斯·柯克·克里斯蒂安森表示：· 过去10年担任乐高基金会主席是我莫大的荣幸，如今能将这一职责移交给阿格妮特，我感到非常高兴。她对乐高基金会的使命怀有深切的热忱，我相信她将竭尽全力，为“保障所有儿童的童年”这一事业贡献力量。“在担任副主席期间，她为制定基金会当前的战略发挥了关键作用。随着她接任主席一职，我们将进一步扩大家族在整个乐高生态系统中的积极所有权和参与度。”托马斯·柯克·克里斯蒂安森自2016年起担任乐高基金会主席，在此期间，基金会通过全球合作伙伴组织承诺拨款超过150亿丹麦克朗（20亿欧元），致力于改善儿童福祉。· “40年来，乐高基金会始终致力于回馈社会，为儿童构建更美好的世界。我们深知家庭和社区对我们的信任，这份责任我们绝不轻视。即使在最艰难的环境中，基金会也能帮助孩子们展露笑颜，激励不同能力水平的学习者，并改变他们的人生轨迹。我们将以最敏锐的洞察力和最负责任的态度践行这一使命，”阿格妮特·柯克·克里斯蒂安森表示。作为乐高集团的股东之一，乐高基金会不仅致力于保障集团的持续发展与成功，更通过资助并紧密合作于Brac、IRC、联合国儿童基金会、救助儿童会、挪威难民理事会等组织，践行其慈善使命，支持教育、研究及儿童发展领域的各项倡议。乐高基金会董事会其他变动除阿格妮特与托马斯·柯克·克里斯蒂安森分别担任主席和副主席外，乐高基金会董事会还在5月的会议上选举英格丽德·斯坦格为董事会成员，她拥有丰富的慈善、教育及非营利组织领导经验。此外，乐高集团前首席执行官约尔根·维格·克努德斯托普（Jørgen Vig Knudstorp）以及红十字会与红新月会国际联合会前秘书长埃尔·哈吉·阿马杜·盖耶·西（El Hadji Amadou Gueye Sy，简称As），在为乐高基金会服务16年和4年后，分别离开了董事会。托马斯·柯克·克里斯蒂安森（Thomas Kirk Kristiansen）对两位离任的董事会成员长期以来对基金会的奉献表示感谢：· 我们非常期待欢迎英格丽德的加入，她将为董事会带来高度互补的专业知识。同时，我感谢阿斯（As）为我们提供了宝贵的见解和经验，帮助塑造了我们的工作。· 我还要向约尔根表达最诚挚的谢意，感谢他对基金会的坚定奉献。在任职期间，约尔根在制定我们的愿景和战略方面发挥了关键作用，同时始终没有忘记我们所服务的儿童。此外，自2021年起担任董事会成员的玛露·阿蒙德，接任了基金会第二副主席的职务。个人简介：阿格内特·柯克·克里斯蒂安森乐高基金会2026年 - 董事会主席2023年至2026年 - 董事会第二副主席2008年起 - 董事会成员KIRKBI A/S2024年 - 董事会副主席ADHD+中心，丹麦奥胡斯创始人奥勒·柯克基金会2025年 - 董事会主席学历2010年，奥胡斯大学心理学专业其他现任及曾任职务：· KIRK83 Holding ApS 执行经理· Ruca 顾问委员会成员· 乐高所有者家族第四代代表· 在家族企业、长期管理及董事会工作中拥有丰富经验乐高基金会董事会阿格内特·柯克·克里斯蒂安森 - 主席托马斯·柯克·克里斯蒂安森 - 第一副主席马洛·阿蒙德 - 第二副主席希拉里·彭宁顿 - 董事会成员英格丽德·斯坦格 - 董事会成员乐高基金会董事会主席1986 - 1993：戈特弗雷德·柯克·克里斯蒂安森（乐高第二代所有者）1993 - 2000：本特·斯科夫2000 - 2016：凯尔德·柯克·克里斯蒂安森（乐高第三代所有者）2016 - 2026：托马斯·柯克·克里斯蒂安森（乐高第四代所有者）2026 - 阿格妮特·柯克·克里斯蒂安森（乐高第四代所有者）关于乐高基金会：乐高基金会是一家丹麦企业基金会，受托持有乐高集团25%的股权。该基金会与全球合作伙伴携手，致力于满足儿童需求，捍卫童年的尊严。通过慈善捐赠和影响力投资，该基金会致力于为世界各地的每个孩子创造茁壮成长的条件和空间。有关乐高基金会的更多信息，请访问： https://www.legofoundation.com/ 联系方式：马德斯·赫维特·格兰德mads.hvitved.grand@legofoundation.com 来源：乐高基金会 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务撮要截至2026年3月31日止三个月(百万港元)20262025变动收入 1,115.61,071.9+ 4.1%毛利402.1376.1+ 6.9%毛利率36.0%35.1%+ 0.9个百分点本公司拥有人应占溢利122.4110.0+ 11.3%纯利率11.0%10.3%+ 0.7个百分点经调整EBITDA209.0201.5+ 3.7%每股盈利（港仙）11.7310.54+ 11.3%香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 日清食品有限公司（「日清食品」或「公司」，连同其附属公司统称「集团」；股份代号：1475）今天公布截至2026年3月31日止三个月（「报告期」）之未经审核第一季度财务业绩。报告期内，集团录得收入1,115.6百万港元，较2025年同期的1,071.9百万港元增加4.1%。毛利按年上升6.9%至402.1百万港元，主要由于持续实施成本效益措施所致。毛利率由2025年同期的35.1%增加0.9个百分点至36.0%，主要由于核心品牌销量增加，消化了成本压力。本公司拥有人应占溢利录得122.4百万港元，按年显著上升11.3%；经调整EBITDA则按年增长3.7%至209.0百万港元。来自香港及其他地区业务的收入增加3.1%，此乃由于面类业务表现稳健，特别是集团核心品牌合味道及出前一丁。内地业务收入增加4.6%，主要受惠于内陆地区的销售扩大及人民币兑港元升值所致。日清食品执行董事、董事长兼首席执行官安藤清隆先生表示：「延续2025年建立的良好增长势头，集团于本季度持续录得稳健的业务表现，主要市场的营运表现保持平稳。收入及盈利按年有所提升，主要受稳定的销售量所支持。核心方便面业务于各地区持续表现理想，而高端化及多元化策略亦于中国内地进一步取得成效。凭借均衡的地域布局及持续提升的营运执行力，集团有信心为股东创造可持续的长远价值。」有关日清食品有限公司日清食品有限公司（「日清食品」，连同其附属公司统称「集团」；股份代号：1475）为一间在中国内地及香港知名的食品公司，主要专营优质方便面市场，旗下众多品牌不仅知名度高，且广受顾客喜爱。集团于1984年正式于香港设立营业据点并为香港最大的方便面公司。集团主要生产及销售两个核心企业品牌「日清」及「公仔」，以及多元化的家庭食品品牌组合，出品具标志性和优质的方便面、优质冷冻食品（包括冷冻点心及冷冻面条）并销售和分销其他食品及饮料产品（包括蒸煮袋装产品、零食、矿泉水、酱料及蔬菜产品）。集团五个旗舰品牌「合味道」、「出前一丁」、「公仔面」、「公仔点心」及「福」在香港亦是其各自食品类别中最受欢迎的选择。中国内地市场方面，集团以创新技术推出「ECO杯」概念，销售活动主要集中在中国内地的一线及二线城市。此外，日清食品在其他地区开展业务，包括越南、台湾、韩国及澳洲市场。日清食品被纳入5项恒生指数，包括恒生综合指数、恒生综合小型股指数、恒生综合行业指数-必需性消费、恒生港股通消费行业指数和恒生港股通食品饮料消费指数。日清食品现可通过沪港通及深港通下港股通进行交易。详情请浏览www.nissingroup.com.hk。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月13日 - (亚太商讯 via SeaPRwire.com) - 中国抗体制药有限公司（"中国抗体"或"公司"，连同旗下附属公司统称"集团"，股份代号：03681.HK）欣然宣布，公司执行董事、主席兼首席执行官梁瑞安博士作为特邀嘉宾，出席了近日在英国伦敦举办的2026 LifeArc转化科学峰会（LifeArc Translational Science Summit）。作为转化医学领域具有全球影响力的盛会之一，本届峰会汇聚了来自世界各地的顶尖科学家、临床医师、行业领袖、政策制定者及投资机构。梁瑞安博士在峰会中发表了主旨报告，系统分享了中国抗体在自身免疫疾病领域的研发策略与核心管线的最新临床进展，并与国际同行展开深入交流。本届峰会由英国知名医学研究慈善机构LifeArc主办。LifeArc长期致力于推动早期科学研究向临床应用的转化，尤其在罕见病及未满足医疗需求领域具有深远影响力。峰会聚焦转化研究如何通过推进新型治疗手段、重塑临床实践、影响卫生政策及驱动商业创新，加速从实验室发现到惠及患者的全过程。与会嘉宾围绕抗体药物、基因治疗、细胞治疗等前沿领域展开跨学科对话，探讨如何破解转化医学中的关键瓶颈，促进产学研医协同发展。梁瑞安博士的受邀，标志着中国抗体在创新免疫治疗领域的探索已获得国际权威机构的高度关注。在峰会主题报告中，梁瑞安博士深入剖析了全球自身免疫疾病药物研发的格局与挑战，并重点阐述了中国抗体以"全球首创（First-in-Class）与同类最优（Best-in-Class）"为核心的差异化创新策略。他详细介绍了公司核心产品SM17——一款靶向白细胞介素25（IL-25）受体的人源化单克隆抗体。SM17通过精准作用于II型免疫反应上游的关键"警戒素"分子IL-25受体，从源头抑制炎症级联反应，具有治疗特应性皮炎（AD）、炎症性肠病（IBD）、哮喘、慢性鼻窦炎伴鼻息肉及特发性肺纤维化等多种炎症免疫性疾病的广阔潜力。梁博士分享了SM17在近期取得的一系列实质性进展：在AD领域，SM17的1b期临床研究显示出卓越的疗效，高剂量组91.7%的患者实现瘙痒缓解（NRS-4），75%达到皮损恢复（EASI 75），41.7%达到完全或近乎完全清除AD症状（IGA 0/1），疗效数据显著优于现有IL-4/IL-13类单抗，且安全性优于JAK抑制剂；基于此，SM17治疗中重度AD的II期临床试验已于2026年3月31日在中国完成首例患者给药，计划入组约210名患者，预计2026年下半年完成全部入组，2027年上半年获得顶线数据。在给药便利性方面，SM17皮下制剂的I期桥接研究于2026年3月25日取得积极顶线结果，30名健康受试者的数据显示皮下注射具有良好的安全性和药代动力学特征，仅有一例1级注射部位皮疹并自行消退，绝对生物利用度稳健，为后续开发更便捷的皮下给药方案奠定了基础。此外，SM17的适应症已成功拓展至IBD，其新药临床试验申请（IND）于2026年2月24日获中国国家药监局正式批准，涵盖克罗恩病及溃疡性结肠炎，相关桥接研究已于2026年2月完成，将直接推进至II期临床开发。梁博士还介绍了公司早期管线的创新布局：抗CGC抗体（全球首创人源化抗γc抗体）在治疗斑秃、白癜风等自身免疫性疾病中展现出潜力，计划于2026年第四季度提交IND申请；靶向RANKL及骨硬化蛋白的双特异性抗体在骨相关适应症的临床前研究中显示出优于现有上市药物的疗效，计划于2027年上半年提交IND申请。梁博士强调，中国抗体通过深耕创新靶点，逐步构建起具有协同效应的产品矩阵，旨在为全球患者提供更安全、更有效、更便捷的突破性治疗方案。此次受邀出席LifeArc转化科学峰会，不仅体现了国际权威机构对中国抗体创新研发实力与前沿探索的高度认可，也为公司深化全球合作提供了重要平台。通过与全球顶尖科学家、临床研究者及跨国药企高管的深入交流，中国抗体进一步拓展了国际学术网络与潜在合作渠道，为未来技术引进、联合研发、对外授权及商业化落地奠定了坚实基础。梁瑞安博士表示，公司将继续聚焦自身免疫性疾病领域未满足的临床需求，加速推进SM17等核心管线的全球多中心临床开发，同时积极探索运用人工智能等新技术赋能新靶点发现，并依托与中山大学香港高等研究院等机构的战略合作，强化从实验室到临床的转化能力。展望未来，中国抗体将把握中国生物医药对外授权高速增长的历史机遇，坚持差异化的全球创新路径，积极寻求与全球伙伴的多元化合作模式，推动创新成果更快惠及全球患者，为股东创造长期价值。关于中国抗体制药有限公司中国抗体制药有限公司（股份代号：03681.HK）是首创新药及潜在同类最佳抗体药物研发领域的开拓者，专注于自身免疫性疾病、以及由此导致的神经系统疾病及其他难治的耗损性疾病，致力于解决未被满足的医疗需求。中国抗体始终致力于开发针对全新靶点及通过创新机制的治疗性抗体，旨在现有疗法效果不佳的领域实现差异化临床成果。其丰富的研发管线包括：SM17在AD治疗中展现出卓越的止痒效果、皮肤清除率及安全性，同时在哮喘和特发性肺纤维化（IPF）领域具有应用潜力；其旗舰抗CD22舒西利单抗，除了临床验证对类风湿关节炎（RA）具有临床疗效外，目前正针对系统性红斑狼疮（SLE）和阿尔茨海默病开展临床评估；另一款抗CGC（共同γ链）创新单抗，正准备进入治疗斑秃和白癜风的临床研究；中国抗体亦研发了一款能同时刺激骨骼生长及抑制骨骼流失、治疗骨质疏松症的双特异性抗体。中国抗体以突破性疗效为核心追求，不断重新定义患者护理标准，稳居突破性疗法领域的领军地位。此新闻稿由真灼财经代中国抗体制药有限公司发布投资者及媒体查询联络人：Bunny LeeNomia ZhouQiuyan Deng电话：（852）5316 9995电邮：ir_sinomab@zhenzhuoglobal.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief Executive Officer of the Company, was invited as a special guest to present at the 2026 LifeArc Translational Science Summit in London,UK. As one of the most influential global events in translational medicine, the summit brought together top scientists, practicing clinicians, industry leaders, policymakers and institutional investors from across the globe. During the event, Dr. Shui On Leung delivered a keynote speech, systematically outlining SinoMab’s R&D strategies for autoimmune diseases and the latest clinical progress of its core pipeline, while engaging in in-depth dialogues with international peers.Hosted by LifeArc, a prestigious UK medical research charity, the annual summit is committed to bridging early-stage scientific research and real-world clinical application, with profound expertise and influence in addressing rare diseases and wide-ranging unmet medical needs. This year’s summit centered on how translational research can accelerate the entire journey from laboratory discoveries to patient access, by advancing novel treatment modalities, transforming clinical practice, shaping health policies and driving commercial innovation. Attendees held interdisciplinary discussions on cutting-edge areas including antibody drugs, gene therapy and cell therapy, exploring solutions to break through core bottlenecks in translational medicine and boost integrated development across industry, academia, research and clinical sectors. Dr. Shui On Leung’s invitation to this high-profile event marks high recognition from leading international authorities of SinoMab’s innovative efforts in immunotherapy.In his keynote address, Dr. Shui On Leung analyzed the current landscape and prevailing challenges in global R&D for autoimmune disease therapeutics, and elaborated on SinoMab’s differentiated innovation framework anchored in “First-in-Class” and “Best-in-Class” drug development. He gave a detailed introduction to SM17, the Company’s flagship humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely binding to IL-25 receptor, a key upstream alarmin molecule regulating type 2 immune responses, SM17 blocks inflammatory cascade reactions at the source. It holds broad therapeutic potential for a spectrum of inflammatory and immune-mediated disorders, including atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Leung shared a series of landmark milestones achieved by SM17 recently. In the AD treatment landscape, Phase 1b clinical data demonstrated outstanding therapeutic efficacy. In the high-dose cohort, 91.7% of patients reported significant itch relief measured by the NRS-4 scale, 75% achieved EASI 75 skin lesion improvement, and 41.7% attained complete or near-complete clearance of AD symptoms (IGA 0/1). Such clinical outcomes outperform existing IL-4/IL-13 targeted monoclonal antibodies, while the product also boasts a more favorable safety profile compared with JAK inhibitors. Building on these promising results, the Phase II clinical trial of SM17 for moderate-to-severe AD completed first patient dosing in mainland China on 31 March 2026. The trial plans to enroll approximately 210 participants, with full enrollment expected in the second half of 2026 and topline clinical data slated for release in the first half of 2027. In terms of administration convenience, the Phase I bridging study of SM17 subcutaneous formulation released positive topline results on 25 March 2026. Data from 30 healthy volunteers confirmed the subcutaneous injection route with satisfactory safety and stable pharmacokinetic performance. Only one mild Grade 1 injection site rash was reported, which resolved spontaneously without intervention, and robust absolute bioavailability was validated, laying a solid foundation for the development of more user-friendly subcutaneous dosing regimens. Furthermore, SM17 has successfully expanded its therapeutic indications to IBD. Its Investigational New Drug (IND) application for Crohn’s disease and ulcerative colitis was officially approved by China’s National Medical Products Administration (NMPA) on 24 February 2026. Relevant bridging studies were finalized in the same month, paving the way for direct progression to Phase II clinical development. Dr. Leung also highlighted the Company’s innovative early-stage pipeline, including the anti-CGC antibody (a first-in-class humanized anti-γc antibody), which has demonstrated potential in the treatment of autoimmune diseases such as alopecia areata and vitiligo, with an IND submission planned for the fourth quarter of 2026. A novel bispecific antibody targeting RANKL and sclerostin has demonstrated superior efficacy over marketed therapies in preclinical studies for bone-related disorders, and its IND filing is targeted for the first half of 2027. Dr. Leung emphasized that by focusing on innovative and untapped drug targets, SinoMab has built a synergistic product portfolio, striving to deliver safer, more effective and more accessible breakthrough therapies for patients worldwide.Being invited to this LifeArc Translational Science Summit is not only a strong recognition from a respected international institution of SinoMab’s innovative edge and exploratory work in antibody R&D, but also a key opportunity to deepen our global partnerships. Through in-depth exchanges with leading scientists, clinical researchers and senior executives of multinational pharmaceutical companies, SinoMab has further expanded its international academic network and potential partnership channels, laying a solid foundation for future technology in-licensing, co-development, out-licensing and commercialization. Dr. Shui On Leung stated that the Company will remains focused on addressing unmet clinical needs in autoimmune diseases. It will accelerate global multi-center clinical development of core pipeline assets such as SM17, while actively exploring how AI and other new technologies can boost novel target discovery. In addition, drawing on strategic collaborations with institutions like the Sun Yat-sen University Institute of Advanced Studies Hong Kong, SinoMab aims to strengthen its translational capabilities from bench to bedside. Looking ahead, SinoMab will seize the rapid growth opportunities in China’s biotech out-licensing market, stay true to a differentiated global innovation path, and actively pursue diversified collaboration models with global partners, and accelerate the delivery of innovative therapies to patients worldwide, while creating long-term value for shareholders.About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeNomia ZhouQiuyan DengPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Anson Resources and POSCO Holdings have received board approval for a binding agreement to develop POSCO's Direct Lithium Extraction ("DLE") Demonstration Plant at the Green River Lithium Project in Utah.POSCO to lead the project at its own expense including the design, construction and operation of its proprietary Direct Lithium Extraction ("DLE") Demonstration PlantPOSCO to pay ~AUD $7.2 million (USD $5.2 million) non-dilutive facilitation fee to Anson.The collaboration positions Green River as a potential cornerstone asset in the emerging U.S. critical minerals and battery supply chain.During operation of the demonstration plant, the parties will evaluate broader commercial opportunities, including potential future joint investment and strategic cooperation.NEWPORT BEACH, CA, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) ("Anson" or the "Company") is pleased to announce that both POSCO Holdings Inc. ("POSCO")'s board and the Company's board have approved the terms for a definitive Demonstration Plant Agreement ("Agreement") relating to the construction and operation of a Direct Lithium Extraction ("DLE") demonstration facility at the Green River Lithium Project in the Paradox Basin, Utah, USA.The board approvals mark a significant progression from the previously announced Memorandum of Understanding (see ASX Announcement 30 June 2025), establishing a framework under which POSCO will operate its own non-commercial DLE demonstration plant designed to validate lithium extraction at continuous industrial scale.Under the agreement POSCO committed to setting up its DLE demo-plant to extract lithium from brines produced from the Bosydaba #1 well owned by Anson at the Green River Lithium Project. POSCO will be responsible for engineering, construction, operation and maintenance of the facility, while Anson will provide access to property, infrastructure and brine supply. POSCO will pay Anson a non-dilutive facilitation fee of AUD ~$7.2 million (USD $5.2 million).The definitive agreement is expected to be signed before the end of Q2 2026. POSCO is expected to commence operation of the demonstration plant in 2027 and complete the work in 2028.The two companies will continue to explore potential business cooperation opportunities, including joint investment in the Project, during the operation of the demonstration plant, as outlined in the MoU Agreement, see ASX Announcement 30 June 2025.Strategic ImportanceDemonstrates strong industry validation of Green River's low-cost lithium potential.Accelerates technical de-risking through continuous demonstration-scale testing.Positions Green River as a key participant in the emerging U.S. domestic battery materials supply chain.Executive CommentaryExecutive Chairman & CEO, Mr. Bruce Richardson commented:"Securing a definitive agreement with POSCO represents a transformational step forward for the Green River Lithium Project.Moving from a non-binding MoU to a fully executed agreement underscores the strong technical confidence POSCO has in our asset and highlights the increasing strategic importance of domestic U.S. lithium supply."POSCO Holdings commented:"With the approval of the terms for a binding agreement, POSCO Holdings will advance validation of DLE technology in the United States and evaluate commercialisation pathways for future lithium production.We believe collaboration with Anson Resources at Green River will contribute to strengthening the North American lithium supply chain."Key Elements of the Definitive AgreementItemKey TermsProjectNon-commercial DLE Demonstration Plant - Green River Lithium ProjectResponsibilityPOSCO to bear cost for the design, construction, operations and maintenance for Demonstration PlantFacilitation FeeUSD $5.2MTermTo December 2028Brine SupplyProvided from Bosydaba #1 well with defined performance targetsAbout POSCO HoldingsPOSCO Holdings Inc. is a leading South Korean industrial group with strategic investments across steel, energy, and battery materials. POSCO Group is developing a global supply chain to support the transition EV and has invested in a total of 93,000 tonnes of lithium production annually in Argentina and South Korea. The company has made significant investments in both brine and hard-rock lithium resources across South America and Australia and is advancing proprietary Direct Lithium Extraction (DLE) technologies to accelerate low-carbon lithium production.This announcement has been authorized for release by the Executive Chairman and POSCO Holdings.For further information please contact:Bruce Richardson Will MazeExecutive Chairman and CEO Head of Investor RelationsE: info@Ansonresources.com E: investors@Ansonresources.comPh: +61 7 3132 7990 Ph: +61 7 3132 7990www.Ansonresources.com Follow us on Twitter @Anson_irSOURCE: Anson Resources Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 12, 2026 - (ACN Newswire via SeaPRwire.com) - Anytime Fitness (the “Company”), a globally renowned 24-hour fitness chain, has seen strong growth across the Asia-Pacific region in recent years. Benefiting from a significant rise in public health awareness in the post-pandemic era, it has continued to accelerate its market expansion. In particular, Hong Kong, as a strategic growth market for the Company, is expected to reach the milestone of 50 clubs by the end of the year. A further 25 clubs have already secured funding, with potential to open an additional 30 to 40 clubs over the next few years. Meanwhile, the Company projects that its total number of clubs across the Asia-Pacific region will reach 2,500 to 3,000 over the next two to three years, underscoring its long-term commitment to and confidence in the regional market.A Truly Global Brand, Powered by Regional ExpertiseAnytime Fitness operates as a truly global brand, with a presence across 42 countries and territories on all seven continents, offering members seamless access to clubs worldwide. Unlike competitors that are merely international, Anytime Fitness delivers a globally connected fitness ecosystem, combining scale, consistency, and member-centric innovation.In Asia-Pacific, growth is led by Inspire Brands Asia (“IBA”), the master franchisee for Anytime Fitness across key markets including Hong Kong, Singapore, Thailand, the Philippines, Indonesia, Vietnam, Taiwan, and Malaysia. This structure enables strong regional execution while maintaining global brand standards.Community-Based Approach: Replicating Singapore’s Success in Hong KongThe core philosophy of Anytime Fitness is to bring fitness services into the community and provide a convenient, stress-free workout experience — a model that has proven successful worldwide. Ryan Cheal, Group Chief Operating Officer of IBA, said: “As a highly mature market in the region, we’ve sold around 200 franchises and operate more than 160 clubs in Singapore. Its market penetration and consumer patterns have provided a clear blueprint for our expansion in Hong Kong. With a similar market profile but a larger population base, Hong Kong offers substantial potential for community-based development. We are confident that we can replicate the success achieved in Singapore, and expect that once Hong Kong surpasses the critical milestone of 50 clubs, network effects will drive even faster growth.”Franchising Drives Scalable Expansion with End-to-End Support for PartnersIn terms of its operating model, Anytime Fitness operates a hybrid model of corporate-owned and franchised clubs. Currently, around 50% of clubs in Hong Kong are corporate-owned, enabling the brand to gain deep insights into the local market and provide more effective support to franchise partners. In contrast, the proportion of corporate-owned clubs in Singapore stands at around 20%. This structure ensures that the Company can maintain high service standards and brand consistency while expanding rapidly.The Company’s franchise ecosystem offers end-to-end support, including:- Site selection and club development; - Equipment and operational setup; - Marketing and member acquisition; - Training and business coaching for franchise partners. This integrated approach ensures consistency in member experience while enabling rapid and sustainable expansion. At present, around 80% of new clubs are opened by existing franchisees. Investors from sectors such as retail and F&B are also increasingly shifting their investments towards the health industry, demonstrating the model’s strong appeal and the market’s recognition of its growth potential.Tech-Powered Member Experience: Building a Comprehensive Health EcosystemIn response to the trend of intelligent transformation, Anytime Fitness is actively leveraging technology to enhance service value. To enhance member experience, Anytime Fitness continues to invest in technology and personalised wellness solutions. Its next-generation member app integrates:- Personalised training plans; - Class and trainer bookings;- Recovery guidance and nutrition support.The ecosystem is further supported by tools such as Evolt, a body composition analysis system capable of measuring over 40 biometric indicators, giving members deeper insight into their health and fitness progress. Currently, the app’s average daily member usage rate is around 30% to 35%, effectively strengthening user engagement and retention.Understanding the Hong Kong Member: Strength, Wellness, and LifestyleRecent member insights highlight evolving fitness priorities in Hong Kong:- 57% of members (3 in 5) prioritise strength training; - 16% (1 in 6) are driven by broader wellness goals, including mental health and overall lifestyle improvement. These trends reflect a structural shift in consumer behaviour, where fitness is no longer discretionary, but an essential part of modern living.Focusing on “Essential Health Needs” and “Human-Centered Connection”, with a Stable and Positive Industry OutlookDespite the complex macroeconomic environment, the Company remains optimistic about the outlook for the industry. Ryan noted that the fitness population is continuing to grow, with participation among seniors steadily increasing and health awareness rising. Consumer spending priorities are also undergoing a structural shift, with health and fitness having evolved from “discretionary spending” to “essential lifestyle”. Notably, younger demographics have shown a particularly strong willingness to invest in health, wellness, and longevity, providing the industry with resilience that transcends economic cycles.Looking ahead, Anytime Fitness will continue to innovate its products and services. It launched a new club design last month, enhancing the strength training and exercise recovery areas, and plans to further improve its nutrition guidance services next year. Ryan concluded, “In this technology-driven era, the Company will continue to uphold the core value of ‘human-centered connection’, using convenient, friendly, and professional services to help more people establish consistent exercise habits and embrace a healthier lifestyle. We are confident in the Asia-Pacific and Hong Kong markets and believe that future growth will be even faster and more innovative.”About Anytime FitnessAnytime Fitness is the largest and fastest-growing global fitness brands in the world, averaging 300 new clubs per year while serving over 5 million members at nearly 6,000 clubs in 42 countries and territories on all seven continents. Open 24-hours a day, 365 days a year, Anytime Fitness delivers personalized and affordable health and wellness training, coaching, nutrition, and recovery guidance for our members—in the club, in their homes, in their pockets, wherever they are and anytime they need it. All franchised clubs are individually owned and operated, and members have access to any Anytime Fitness club worldwide.For more information, please visit：https://www.anytimefitness.com/.Media Inquiries:Inspire Brand AsiaJerry Chow Email: Jerry.chow@inspirebrandsasia.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAMPA, FLA., May 12, 2026 - (ACN Newswire via SeaPRwire.com) - The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, named V.S. Hariharan, Managing Director and Group CEO of Redington Limited, to its Executive Committee. The committee provides operational oversight and helps guide GTDC's long-term strategy, advancing the organization's mission to strengthen distribution's role in the global technology marketplace."Hari is a respected global IT leader and a strong advocate for distribution," said Frank Vitagliano, CEO of GTDC. "He brings valuable insight to our leadership team and will help shape our long-term strategy and initiatives that highlight the expanding role of distributors in today's technology ecosystem."GTDC's executive leadership group oversees the organization's vision, develops and updates its strategic plans and advocates for its members' common interests. Comprised of senior executives from member distributors, the EC carries out the non-profit association's mission to educate, advocate and influence the tech community on the evolving role of IT distributors. Council leaders also sponsor and oversee GTDC research, the association's three regional executive level events and other member driven initiatives. Hariharan will support these efforts, strengthening partnerships between distributors and vendors and reinforcing distribution's value across the global technology marketplace."Delivering innovative solutions that meet the evolving needs of the technology community has been my core focus at Redington, and I look forward to working with other distribution leaders to serve GTDC in a similar capacity," said Hariharan. "As a Technology Orchestrator, we are focused on connecting partners, platforms and possibilities to unlock next opportunities across markets. I see this role as a natural extension of that commitment, and look forward to strengthening collaboration, sharpening our view of global industry trends, and helping the ecosystem navigate the opportunities and challenges ahead."Hariharan is the Managing Director and Group CEO of Redington, an $11.8 billion distribution and supply chain solutions provider, where he leads operations across 40 markets. A seasoned industry leader, he brings over 35 years of experience across sales, marketing, and general management, including senior leadership roles at Hewlett Packard and Wipro Infotech, along with entrepreneurial experience in scaling solar solutions for off grid markets.Under his leadership, Redington is accelerating its role as a Technology Orchestrator, bringing together OEMs and partnersQ to drive innovation, agility, and growth across emerging markets.About the GTDCThe Global Technology Distribution Council is the industry consortium representing the world's leading technology distributors. GTDC members drive an estimated $180 billion in annual worldwide sales of products, services and solutions through diverse business channels. GTDC conferences foster strategic supply-chain partnerships that address the fast-changing needs of vendors, end customers and distributors. Members include AB S.A, Arrow Electronics, CMS Distribution, Computer Gross Italia S.p.A., D&H Distributing, ELKO Group, Esprinet S.p.A., Exclusive Networks, Exertis, Infinigate, Ingram Micro, Intcomex, Logicom Public Limited, Mindware, Nexora, Redington Limited, SiS Technologies, Tarsus Distribution, TD SYNNEX, TIM AG and Westcon-Comstor.Brian ShermanCommCentric Solutions (on behalf of GTDC)814-882-4432bsherman@commcentric.comSOURCE: Global Technology Distribution Council Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - May 12, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has signed a 3 year lease, with options for term extension, to support production expansion and to provide additional office space for staff. The site is within the Richlands suburb of Brisbane, nearby to the existing headquarters of the Company. The site has over 2,100 square metres of covered space — including offices, meeting rooms and a high ceiling warehouse.Craig Nicol, CEO & Managing Director of the Company, commented "This is the first site for expansion for our company — for both staff and production assets. We will look to expand our production assets here after the Gen 2 Project is completed — which is expected at the end of June 2026."Jack Perkowski, Non-Executive Chairman and Director of the Company, commented: "As we look to expand our production plants around the world — this is the first significant step in our global growth plan."Operations UpdateGMG is focused on delivering its Gen 2.0 Graphene Production Project (the "Gen 2.0 Project") by end of June 2026 — which is expected to produce at least 10 tonnes per annum of graphene at its headquarters in Richlands, Queensland, Australia.Once the Gen 2.0 Project is commissioned and operating, GMG plans to replicate and establish other production plants around the world to enable scaled production for potential sales, diversify and lower production risks, and reduce operating costs by locating the plant in countries with lower operating costs, including low cost natural gas — one of GMG's key production input costs.Currently, GMG is planning three potential expansion projects — two in North America (potentially one in US and one in Canada) in addition to an expansion production project in Australia (located on the expansion lease outlined in this release). GMG proposes to mature these projects and expand production in line with sales for all of its products.The expansion program for GMG includes the following 5 production plants:Graphene Production (from natural gas)Coating Blend Plant (for the graphene coating THERMAL-XR®)Lubricant Blend Plant (for the graphene lubricant additive G® LUBRICANT)Graphene Slurry Plant (for the SUPA G Lithium-Ion Battery Additive)Battery Assembly Plant (for the Graphene Aluminium Ion Battery)Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/297118_53e7bb85547cbaac_001full.jpgAbout GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements as to GMG's focus on, and the timing and production expectations of, the Gen 2 Project, intentions regarding the number, purpose and location of expansion projects, intentions to de-risk, reduce operating costs and develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialization of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and GMG's critical business objectives.Such forward-looking statements are based on a number of assumptions of management, including the patent and potential market size of G® LUBRICANT. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297118 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CALGARY, AB AND VANCOUVER, BC / ACN Newswire via SeaPRwire.com / May 12, 2026 / CANEX Metals Inc. ("CANEX") (TSXV:CANX) and Gold Basin Resources Corporation ("Gold Basin") (TSXV:GXX) are pleased to announce that they have entered into a definitive agreement (the "Arrangement Agreement") to combine their respective businesses by way of a plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement"). The combined company will be managed by the CANEX executive team.Under the terms of the Arrangement, shareholders of Gold Basin ("Gold Basin Shareholders") will receive 0.592 shares of CANEX ("CANEX Shares") per share of Gold Basin ("Shares") held, the same consideration received by Gold Basin Shareholders who tendered to the CANEX offer to acquire Shares which expired on February 10, 2026. This represents a premium of 242.0% to the last trading price of the Shares prior to the Cease Trade Order, based on the closing price of the CANEX Shares as of May 8, 2026.Dr. Shane Ebert, President and CEO of CANEX stated: "Today's announcement of an agreement to combine the two companies will allow us to consolidate and advance a promising gold district in Arizona. CANEX will be pleased to welcome Gold Basin Shareholders as new shareholders of CANEX."Jordan Ross, independent director and Chair of the Gold Basin Special Committee, commented: "The Arrangement Agreement represents a strategic milestone for our shareholders. By partnering with CANEX, we are unlocking the full potential of our Arizona project while providing a stable, clear-cut path forward that resolves previous liquidity and regulatory challenges. Following a rigorous review with our professional advisors, we are confident this agreement offers the most robust and value-driven future for our investors."Benefits to Gold Basin ShareholdersSignificant Upfront Premium to Shareholders. The consideration offered under the Arrangement represents a 242.0% premium to the last trading price of the Shares prior to the Cease Trade Order, based on the closing price of the CANEX Shares as of May 8, 2026.Consolidation of Gold Districts and Near-Term Exploration and Expansion. The Arrangement will consolidate an advanced oxide gold exploration camp in Mohave County, Arizona hosting multiple zones of gold mineralization with strong drill results across an eight kilometre by eight kilometre area, opening up potential near-term exploration on favourable targets.Diversification. Completing the Arrangement will provide Gold Basin Shareholders not only with exposure to a consolidated gold district in Mohave County, Arizona, but also to CANEX's Louise Project in British Columbia. On July 31, 2025, CANEX announced results from an induced polarization geophysical survey which identified a new and previously unknown chargeability target two kilometres west of the historic Louise deposit and a large steeply dipping zone of high chargeability below and to the north of the historic Louise deposit.Focused, Professional and Cost-Effective Management Team. The Arrangement places the consolidated district under CANEX's highly focused, professional and cost-effective management team, which will provide strong operational and governance oversight.Experienced Board of Directors. Following the Arrangement, the Resulting Issuer's board of directors will be led by experienced industry professionals, comprised of members of the current board of directors of CANEX.Liquidity. The Arrangement will provide Gold Basin Shareholders with a more liquid investment. On May 6, 2025, the British Columbia Securities Commission imposed a Cease Trade Order against the Gold Basin Shares. The next day, the Canadian Investment Regulatory Organization imposed a halt in trading of the Gold Basin Shares on the TSXV. There is no expectation that the Cease Trade Order will be rescinded if the Arrangement were not to proceed and Gold Basin were to continue with the status quo.Enhanced Financial Capacity. CANEX has demonstrated an ability to raise capital and has strong support from a number of high profile industry professionals. With an enhanced capital markets profile, the Resulting Issuer is expected have even better access to lower-cost capital and an increased capability to advance its exploration properties.Going Concern. In the absence of the Arrangement, there is considerable risk that Gold Basin will not have the ability to continue as a going concern and realize its assets and discharge its liabilities in the normal course of business. Currently, Gold Basin has asserted liabilities of over $2 million, no cash or marketable securities and no revenue. Gold Basin's ability to raise equity financing is restricted by the Cease Trade Order.Details of the ArrangementCANEX and Gold Basin entered into a definitive Arrangement Agreement on May 11, 2026, pursuant to which CANEX will acquire all of the issued and outstanding common shares of Gold Basin ("Gold Basin Shares") by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia).Holders of Gold Basin Shares ("Gold Basin Shareholders") will receive 0.592 common shares in the capital of CANEX (the "CANEX Shares", and such ratio being the "Exchange Ratio") in exchange for each Gold Basin Share held immediately prior to the effective time of the Arrangement. Upon completion of the Arrangement, existing holders of CANEX Shares and former Gold Basin Shareholders will own approximately 67.7% and 32.3% of the total issued and outstanding CANEX Shares, respectively, on a fully diluted basis.CANEX expects to issue an aggregate of approximately 38,505,033 CANEX Shares to Gold Basin Shareholders, based on the number of Gold Basin Shares outstanding as at the date of this announcement.The Arrangement is expected to close in June 2026, subject to the receipt of all required court, shareholder, regulatory, and stock exchange approvals. Following completion of the Arrangement, the CANEX Shares will remain listed on the TSXV and the Gold Basin Shares will be delisted from the TSXV.Term LoanConcurrently with the entering into of the Arrangement Agreement, CANEX and Gold Basin have agreed to enter into a senior secured term loan (the "Term Loan") as soon as practicable pursuant to which CANEX will lend up to $900,000 to Gold Basin at an interest rate per annum equal to the Royal Bank of Canada Prime Rate plus 5.0%. The maturity of the Term Loan shall be six months and the Term Loan shall be secured by a first ranking general security agreement over all of Gold Basin's present and after-acquired assets, a first ranking mortgage charge over Gold Basin's split mineral rights and first ranking security agreements encumbering all of Gold Basin's other mineral tenure. The proceeds from the Term Loan will be used by Gold Basin for aged payables, day to day working capital and general corporate expenditures, direct advances paid by CANEX to third party suppliers, service providers and creditors of Gold Basin, and expenses in connection with the Arrangement. The Term Loan is not contingent on the completion of the Arrangement.The Term Loan is subject to the approval of the TSXV. No fees are payable in connection with the Term Loan.Arrangement Conditions and TimingThe Arrangement will be effected by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) and will require the approval of: (i) at least 66⅔% of votes cast by Gold Basin Shareholders, and (ii) a simple majority of the votes cast by disinterested Gold Basin Shareholders, excluding for this purpose the votes held by any person specified under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. The Gold Basin Shares held by CANEX will not be excluded from either vote. CANEX currently holds 70,088,199 Gold Basin Shares, representing 51.86% of the issued and outstanding Gold Basin Shares.The Arrangement Agreement includes customary representations and warranties for a transaction of this nature as well as customary interim period covenants regarding the operation of CANEX's and Gold Basin's businesses. The Arrangement Agreement also includes customary deal protections in favour of each of CANEX and Gold Basin. With respect to CANEX, these protections include non-solicitation covenants, and a right to match any superior proposals. With respect to Gold Basin, these protections include a fiduciary-out provision. The Arrangement Agreement includes a termination fee of $211,777 payable by Gold Basin in the event the Arrangement Agreement is terminated in certain circumstances.In addition to securityholder and court approvals, the Arrangement is subject to applicable regulatory approvals, stock exchange approvals and the satisfaction of certain other closing conditions customary in transactions of this nature.None of the securities to be issued pursuant to the Arrangement have been or will be registered under the U.S. Securities Act, or any state securities laws, and any securities issuable in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.Further details of the Arrangement will be included in a management information circular to be prepared by Gold Basin (the "Gold Basin Circular") that will be delivered to Gold Basin Shareholders in advance of a special meeting of Gold Basin Shareholders (the "Gold Basin Meeting") which is scheduled to be held on June 4, 2026. A copy of the Arrangement Agreement will be made available on CANEX's and Gold Basin's respective SEDAR+ profiles at www.sedarplus.com. The Gold Basin Circular will also be made available on Gold Basin's SEDAR+ profile in advance of the Gold Basin Meeting.Board of Directors' and Special Committee RecommendationBased on the recommendation of a special committee comprised of an independent director of Gold Basin (the "Special Committee") and after consultation with independent external financial and legal advisors, the board of directors of Gold Basin (the "Gold Basin Board") unanimously approved the Arrangement and has determined the Arrangement is in the best interests of Gold Basin, and that the consideration to be received by Gold Basin Shareholders is fair, from a financial point of view, to Gold Basin Shareholders (other than CANEX). The Gold Basin Board unanimously recommends that Gold Basin Shareholders vote in favour of the Arrangement at the Gold Basin Meeting.Stifel Nicolaus Canada Inc. has provided a fairness opinions to the Gold Basin Board and Special Committee in connection with the Arrangement.Voting Support AgreementsEach of Gold Basin's directors and officers support the Arrangement and all who own Shares have entered into customary voting support agreements agreeing to vote their Gold Basin Shares, respectively, in favor of the Arrangement. The voting support agreement may be terminated in certain circumstances, including, without limitation, upon termination of the Arrangement Agreement.About CANEX MetalsCANEX Metals (TSX.V:CANX) is a Canadian junior exploration company and the controlling shareholder of Gold Basin Resources, owning 51.86% of Gold Basin. CANEX is advancing its 100% owned Gold Range Project in Mohave County, Arizona. With several near surface bulk tonnage gold discoveries made to date across a 4 km gold mineralized trend, the Gold Range Project is a compelling early-stage opportunity for investors. Gold Basin Resources holds the adjacent Gold Basin Project which hosts large, mineralized trends containing near surface oxide gold mineralization and has seen over 800 historic and current drill holes into mineralized deposits up to 1.7 kilometres in length.CANEX is also advancing the Louise Copper-Gold Porphyry Project in British Columbia. Louise contains a large historic copper-gold resource that has seen very little deep or lateral exploration, offering investors copper and gold discovery potential. CANEX is led by an experienced management team which has made three notable porphyry and bulk tonnage discoveries in North America and is sponsored by Altius Minerals (TSX: ALS), a large shareholder of the Company.About Gold Basin Resources CorporationGold Basin Resources Corporation holds the Gold Basin Project in Mohave County Arizona. The project hosts large, mineralized trends containing near surface oxide gold mineralization and has seen over 800 historic and current drill holes into mineralized deposits up to 1.7 kilometres in length."Shane Ebert"Shane Ebert, President/Director of CANEX and Gold BasinFor Further Information Contact:Shane Ebert at 1.250.964.2699 orJean Pierre Jutras at 1.403.233.2636Web: http://www.canexmetals.caNeither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Although information provided by Gold Basin for inclusion in this news release is believed by CANEX to be reliable, CANEX has not independently verified such information and cannot provide any assurance of its accuracy, currency, reliability or completeness. Although information provided by CANEX for inclusion in this news release is believed by Gold Basin to be reliable, Gold Basin has not independently verified such information and cannot provide any assurance of its accuracy, currency, reliability or completeness.Forward-Looking StatementsThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", "potential", "risk", "anticipated", "future", or "opportunity" or variations of such words and phrases or stating that certain actions, events or results "may", "can", "shall" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.In this news release, forward-looking statements relate to, among other things, statements regarding: the proposed acquisition by CANEX of all of the Gold Basin Shares pursuant to the Arrangement and the terms thereof; the benefits of the Arrangement; the receipt of necessary shareholder, court and regulatory approvals for the Arrangement; the anticipated timeline for completing the Arrangement; the Gold Basin Meeting and mailing of the management information circular regarding the same; the Term Loan; the terms and conditions pursuant to which the Arrangement will be completed, if at all; the anticipated benefits of the Arrangement; the anticipated filing of materials on SEDAR+; and continuation of CANEX and delisting of Gold Basin. These forward-looking statements are not guarantees of future results and involve risks and uncertainties that may cause actual results to differ materially from the potential results discussed in the forward-looking statements.In respect of the forward-looking statements, CANEX and Gold Basin have relied on certain assumptions that they believe are reasonable at this time, including assumptions as to the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court, shareholder, stock exchange and other third party approvals and the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Arrangement. This timeline may change for a number of reasons, including unforeseen delays in preparing meeting materials; inability to secure necessary regulatory, court, shareholder, stock exchange or other third-party approvals in the time assumed or the need for additional time to satisfy the other conditions to the completion of the Arrangement. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times.Risks and uncertainties that may cause such differences include but are not limited to: the risk that the Arrangement or the Term Loan may not be completed on a timely basis, if at all; the conditions to the consummation of the Arrangement or the Term Loan may not be satisfied; the risk that the Arrangement or the Term Loan may involve unexpected costs, liabilities or delays; the possibility that legal proceedings may be instituted against CANEX, Gold Basin, and/or others relating to the Arrangement or the Term Loan and the outcome of such proceedings; the possible occurrence of an event, change or other circumstance that could result in termination of the Arrangement Agreement; risks relating to the failure to obtain necessary regulatory, court, shareholder, and stock exchange approvals; other risks inherent in the mining industry. Failure to obtain the requisite approvals, or the failure of the parties to otherwise satisfy the conditions to or complete the Arrangement or Term Loan, may result in the Arrangement or Term Loan not being completed on the proposed terms, or at all. In addition, if the Arrangement or Term Loan are not completed, the announcement of the Arrangement and the Term Loan and the dedication of substantial resources of CANEX and Gold Basin to complete the Arrangement and the Term Loan could have a material adverse impact on each of CANEX's and Gold Basin's share price, its current business relationships and on the current and future operations, financial condition, and prospects of each of CANEX and Gold Basin. CANEX and Gold Basin disclaim any responsibility to update these forward-looking statements, except as required by applicable laws.SOURCE: Gold Basin Resources Corporation Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 12, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, successfully assisted the State Bank of Mongolia in completing a US$100 million Reg S bond tap issuance as the sole global coordinator. This issuance is a tap-on of the State Bank (Mongolia) initial US$ 200 million 3-year bond issued in September 2025. Upon completion of this tap issuance, the outstanding size of the bond has increased to US$300 million.The issuer has been assigned a “B1” issuer rating by Moody’s, with a “stable” outlook, aligned with Mongolia’s sovereign rating. This issuance also received formal support letters from the Ministry of Finance of Mongolia and the Central Bank of Mongolia. The tap offering was priced at a yield of 8.5%, representing a significant improvement from the original issuance's level of 8.9%. This not only reflects the solid financial fundamentals of the State Bank (Mongolia), but also signals continuously growing confidence among international investors in Mongolia’s economic prospects.The successful completion of this bond tap issuance marks a significant milestone for the State Bank (Mongolia) in the international capital markets. It also represents another in-depth collaboration between the bank and GTJAI, following the latter’s assistance in the bank’s initial US$200 million 3-year bond issuance in September 2025, demonstrating the high level of mutual trust and long-term rapport between the two parties. Amid a complex and volatile global capital market environment, GTJAI precisely seized the market window and efficiently executed the project. This not only further strengthens the Company’s business presence in facilitating offshore bond financing for issuers outside the Greater China region, but also fully showcases its capabilities in professional pricing, global investor resource integration, and cross-market comprehensive financial services in the global capital markets.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月12日 - (亚太商讯 via SeaPRwire.com) - 近日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"，股份代号：1788.HK）作为独家全球协调人，圆满协助蒙古国家银行（State Bank of Mongolia）完成1亿美元Reg S债券增发。本次发行为蒙古国家银行2025年9月首次2亿美元3年期债券的增发，发行完成后，该期债券存续规模增至3亿美元。发行人获穆迪授予"B1"发行人评级，评级展望"稳定"，与蒙古主权评级一致。本次发行亦获得蒙古财政部及蒙古中央银行出具的正式支持函。本次增发定价收益率为8.5%，较原发行8.9%的水平显著优化，既体现蒙古国家银行稳健的财务基本面，也反映国际投资者对蒙古经济前景的信心持续提升。 本次债券增发顺利落地，是蒙古国家银行在国际资本市场的重要里程碑，亦是国泰君安国际继2025年9月助力其首次完成2亿美元3年期债券后，与该行的再度深度合作，彰显双方高度互信与长期默契。面对复杂多变的全球资本市场环境，国泰君安国际精准把握市场窗口、高效完成项目执行，既进一步巩固了公司服务非大中华区域发行人开展境外债券融资的业务布局，也充分展现了其在全球资本市场的专业定价、全球投资者资源整合及跨市场综合金融服务能力。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK），是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高质量、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"AAA"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的信息请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 12, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) ("CASA" or the "Company") is pleased to report that it has received aggregate gross proceeds of $432,777.30 to date in 2026 through the exercise of 4,453,364 common share purchase warrants (the "Warrants").The Warrants were originally issued pursuant to the Company's private placements completed in April of 2025 and February of 2026. Each Warrant entitled the holder to acquire one common share of the Company upon exercise.Net proceeds will be deployed to advance Casa's 2026 exploration programs at the Congress Gold Mine in Arizona and the Arsenault Copper-Gold-Silver Project in British Columbia, and for general working capital purposes."The continued support from our warrant holders is greatly appreciated," said Farshad Shirvani, President and Chief Executive Officer. "This additional capital meaningfully strengthens our balance sheet as we mobilize for an aggressive 2026 drilling and exploration season across our core projects."About Casa Minerals Inc.Casa Minerals Inc. is a mineral exploration company focused on gold, copper, and strategic minerals exploration in North America. The Company holds a 90% interest in the historic Congress Gold Mine in Arizona and is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project. Casa's experienced management team is committed to creating shareholder value through the discovery and development of economic mineral deposits. For more information, please visit: www.casaminerals.comON BEHALF OF THE BOARD OF DIRECTORSFarshad Shirvani, M.Sc. GeologyPresident, CEO and DirectorFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297081 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月12日 - (亚太商讯 via SeaPRwire.com) - 全球知名24小时连锁健身品牌Anytime Fitness（"公司"）近年于亚太区发展强劲，受惠于后疫情时代公众健康意识显著提升，市场拓展步伐持续加快。其中，香港作为策略性增长市场，预计年内场馆总数达50间之里程碑，另有逾25间已获资金支持，未来数年更有潜力增设30至40间场馆。同时，公司预测未来二至三年，亚太区场馆总数将达2,500至3,000间，展现其对区域市场的长期承诺与信心。真正全球品牌 区域专业赋能Anytime Fitness作为真正的全球品牌，业务覆盖7大洲共42个国家及地区，会员可于全球各场馆无缝畅行。不同于同业仅具国际化布局，Anytime Fitness构建了全球互联的健身生态体系，兼具规模优势、服务一致性，以及以会员为本的创新能力。于亚太区，Inspire Brands Asia（"IBA"）作为Anytime Fitness在香港、新加坡、泰国、菲律宾、印尼、越南、台湾及马来西亚等重点市场的总特许经营商，推动业务增长。此架构既有助于强化区域执行力，又能维持全球品牌标准的一致性。以社区为本 复制新加坡经验至香港Anytime Fitness的核心理念是将健身服务带入社区，并提供便捷、无压力的健身体验，此模式于全球验证成功。IBA集团首席营运总裁Ryan Cheal表示："新加坡作为区域内高度成熟的市场，已授出约200个特许经营权，营运场馆逾160间，其市场渗透率与消费模式为香港提供了清晰的发展蓝图。香港与新加坡市场高度相似，且人口基数更大，极具社区发展潜力。我们有信心复制新加坡的成功经验，预计香港于突破50间场馆之临界点后，网络效应将带动更快增长。"特许经营驱动规模扩张 全链支持合作伙伴营运模式方面，Anytime Fitness 采用特许经营与直营并行。目前香港约50%场馆为品牌直营，此举旨在深入理解本地市场，以更有效地支持特许经营合作伙伴。另外，新加坡市场的直营比例约20%，此结构确保公司于快速扩张的同时，能维持高品质的服务标准与品牌一致性。公司特许经营生态提供全链支持，包括：- 选址及场馆建设；- 设备配置及营运筹备；- 营销及会员招募；- 特许经营合作伙伴培训及业务指导。此整合模式既可确保会员体验的一致性，又能实现迅速且可持续的扩张。目前，公司约80%的新增场馆来自现有特许经营商，零售、餐饮等行业投资者亦呈转投健康产业之趋势，印证了该模式的强大吸引力与市场对其增长潜力的认可。科技赋能会员体验 构建全方位健康生态面对智慧化趋势，Anytime Fitness积极以科技提升服务价值。为提升会员体验，Anytime Fitness 持续投资于科技及个人化的健康方案，其新一代会员应用程式整合以下功能：- 个人化训练计划；- 课堂及教练预约；- 恢复指导及营养建议。此生态系统亦配备多种仪器，例如Evolt身体成分分析仪，可测量逾40项生物指标，令会员更深入掌握自身健康与健身进展。目前，应用程式日均会员使用率约30%至35%，有效巩固用户参与度与黏性。洞悉香港会员：力量训练、身心健康与生活方式最新会员洞察显示，香港会员的健身目标优先级正在转变：- 57%的会员（每五人中有三人）以力量训练为首要目标；- 16%的会员（每六人中有一人）则更注重整体健康，包括心理健康及整体生活方式的改善。上述趋势反映出消费者行为的结构性转变：健身不再只是可有可无的选择，而是现代生活不可或缺的一部分。聚焦"健康刚需"与"人性化连接" 行业前景稳健向好尽管宏观经济仍显复杂，公司对行业前景保持乐观。Ryan指出，当前健身人群持续扩大，长者参与健身人数逐步上升，健康意识亦不断提升；大众消费优先次序正经历结构性转变，健康与健身已由"可选消费"转变为"生活必需"。值得一提的是，年轻族群对健康、保健与长寿的投资意愿尤为显著，为行业带来穿越周期的韧性。展望未来，Anytime Fitness将持续进行产品与服务创新。公司已于上月推出全新场馆设计，强化力量训练与运动恢复区域，并计划于明年进一步优化营养指导服务。Ryan总结："科技时代，Anytime Fitness 将坚持‘人性化连接’的核心价值，以便利、友善、专业的服务，令更多人建立恒常运动习惯，开启健康生活。我们对亚太及香港市场充满信心，相信未来发展将更快速、更具创新性。"关于Anytime FitnessAnytime Fitness是全球规模最大、发展最快的健身品牌之一，每年新增场馆约300间，现已覆盖全球7大洲42个国家和地区的逾5,600间场馆，为逾500万会员提供服务。无论会员身处何方，该品牌都能全年365天、全天24小时开放，随时为会员于场馆、家中和移动设备上，提供他们所需的个性化、可负担的健康保健训练、指导、营养和恢复服务。所有特许经营的场馆均为独立所有及营运，会员可以进入全球任一Anytime Fitness场馆。如欲索取更多资料，请浏览以下网址：https://www.anytimefitness.com/。新闻垂询：Inspire Brand AsiaJerry Chow 电邮: Jerry.chow@inspirebrandsasia.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MUMBAI, INDIA, May 12, 2026 - (ACN Newswire via SeaPRwire.com) - CleverTap, the all-in-one customer engagement platform, has won Silver at the Thailand MarTech Awards 2026 in the Impact MarTech category, in partnership with Rabbit Rewards, the loyalty and lifestyle platform for Bangkok’s BTS Skytrain and a widely used commuter ecosystem in Southeast Asia.The recognition highlights how CleverTap and Rabbit Rewards have transformed customer engagement by building a real-time, agentic engagement model powered by autonomous decisioning, designed to serve millions of commuters in a high-frequency environment.Rabbit Rewards operates at the intersection of daily commuting, payments, and lifestyle services, where user behavior shifts constantly based on routine, timing, and location. Traditional campaign-led approaches, built on static segmentation and fixed schedules, were unable to keep pace and often resulted in delayed or irrelevant engagement.To address this, Rabbit Rewards partnered with CleverTap to implement a real-time decisioning layer that continuously interprets live behavior and determines the next best action for each user.With CleverAI™, and its suite of tools — including IntelliNODE and Best Time Optimization among others — Rabbit Rewards deployed trigger-based, omnichannel journeys across push notifications, in-app messaging, email, and SMS. These journeys span onboarding, renewals, promotions, and re-engagement, and adapt continuously to commuter behavior.The shift to real-time, behavior-led engagement delivered clear, measurable outcomes:85% uplift in click-through rates (CTR)62.6% week-4 repeat transactions among engaged users, compared to 18.7% for non-engaged users2.4% of total transactions directly influenced by CleverTap-powered engagementBeyond these results, Rabbit Rewards significantly improved the quality of customer engagement. Communication became more timely, contextual, and aligned with commuter needs, strengthening trust and positioning the platform as a more intuitive, lifestyle-oriented companion for daily users.“Our vision has always been to make everyday commuting more seamless, rewarding, and relevant for our users. Through our partnership with CleverTap, we have successfully transitioned from traditional campaign execution to a real-time engagement model that understands and responds to commuter behavior in the moment.CleverAI™ has enabled us to deliver more personalized and timely experiences at scale, strengthening both customer engagement and long-term loyalty. This collaboration goes beyond technology — it is about ensuring Rabbit Rewards shows up for our members in ways that feel personal, timely, and genuinely useful throughout their daily journeys,” said Kamolwan Korphaisarn, Program Director, Rabbit Rewards“Enterprises today sit on a surplus of data, but turning those data points into timely, meaningful action remains a big challenge. With CleverAI™, we’re enabling brands to move beyond static campaigns to intelligent systems that continuously interpret behavior, determine the next best action, and deliver truly personalized experiences in real time. Our work with Rabbit Rewards shows how this approach drives stronger engagement while enabling seamless, context-aware customer journeys at the scale of the individual,” said Anand Jain, Co-founder and Chief Marketing Officer, CleverTap.About Rabbit RewardsRabbit Rewards is Thailand’s leading loyalty and lifestyle platform built around Bangkok’s BTS Skytrain ecosystem, one of Southeast Asia’s busiest urban transit networks serving millions of daily commuters.The platform connects commuting, payments, and everyday lifestyle experiences into a single ecosystem, enabling members to access rewards, offers, and partner benefits across Bangkok.As part of BTS Group Holdings, Rabbit Rewards serves a diverse member base ranging from daily riders and students to tourists and lifestyle-focused members, making it a deeply embedded companion in Bangkok’s urban lifestyle.Rabbit Rewards continues to evolve its customer engagement capabilities to deliver more contextual, real-time experiences that align with the rhythm of everyday commuting and lifestyle needs.For more information, visit rabbitrewards.co.thAbout CleverTapCleverTap is the world’s leading AI-first, all-in-one customer engagement and retention platform, helping brands turn data into lasting customer relationships. Powered by its proprietary CleverAI™: Decisioning Engine and Agentic AI-verse, CleverTap enables organizations to maximize customer lifetime value at scale. Its unified platform brings together AI-powered segmentation, personalization, experimentation, journey orchestration, and deep analytics—seamlessly integrated with 100+ leading martech solutions.Leading brands such as Burger King, Levi’s, IKEA, Decathlon, Domino’s, Jio, Carousell, AIA Thailand, Sasom, 12Go, and Ngern Tid Lor, rely on CleverTap to drive measurable growth through meaningful customer engagement. With backing from global investors including Accel, Peak XV Partners, Tiger Global, CDPQ, and 360 One, CleverTap has presence across US, Europe, the Middle East, Latin America, and Asia.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/X: https://twitter.com/CleverTapFor more information:ADITYA SANYALDirector, Digital Marketing, CleverTap+91 9177110080aditya.sanyal@clevertap.comASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 12, 2026 - (ACN Newswire via SeaPRwire.com) - May 11, 2026, Gold Peak Technology Group Limited (SEHK: 40) completed a syndicated green and sustainability-linked loan facility (the “GSLL Facility”) of HK$675 million with 10 major banks. With Hang Seng Bank Limited as the mandated lead arranger and bookrunner, Shanghai Commercial Bank Limited is the mandated lead arranger and Malayan Banking Berhad the lead arranger. Other arrangers include Chang Hwa Commercial Bank, Ltd. Hong Kong Branch; Bank of Dongguan International Limited; China Zheshang Bank Co., Ltd. Hong Kong Branch; Taiwan Cooperative Bank, Ltd. Hong Kong Branch; Taiwan Shin Kong Commercial Bank Co., Ltd., Hong Kong Branch; First Commercial Bank, Ltd., Macau Branch; and Hua Nan Commercial Bank, Ltd., Offshore Banking Branch.Notwithstanding the challenging global environment, this HK$675 million GSLL Facility underscores strong confidence and backing from the banking sector in Gold Peak’s commitment to, and track record of, upholding and advancing Environmental, Social, and Governance (“ESG”) principles.Victor Lo, Chairman & Chief Executive of Gold Peak, said, “Gold Peak remains steadfast in its commitment to long-term sustainable development and has consistently demonstrated its ability to deliver in this area. The establishment of the GSLL Facility not only validates our strategic direction but also enables us to explore innovative financing options and adopt operational best practices that will drive sustainable business growth.”Dr Brian Li, Vice Chairman and Executive Vice President of Gold Peak, commented, “As a prominent player in the batteries, audio, and electronics industries, Gold Peak is committed to embedding sustainability into every aspect of its operations. We have made solid and measurable progress in advancing our sustainability strategy, reflecting our dedication to responsible corporate citizenship and long-term value creation.”“We champion the use of rechargeable batteries to reduce waste. Our GP Recyko rechargeable range has been met with strong market acceptance, and we are continuously improving our charging efficiency to enable full charging in just one hour, a boost to shifting the consumers’ habit from single-use batteries to rechargeables.”“We continued to reinforce our packaging sustainability efforts by replacing plastic packaging with paper-based alternatives for more than 1,000 GP-branded consumer battery products across Europe. As a result of this initiative, we achieved an annual reduction of 48 tons of plastic and 30 tons of material waste.”GP Energy Tech, the Group’s sustainable energy solutions business, reached a key milestone with the opening of our first Nickel Zinc (NiZn) manufacturing facility in Dongguan, China, in January 2026. This marks an important step toward positioning Gold Peak to develop next- generation NiZn battery solutions, engineered to enhance immediate power performance through high power density, improved recyclability, and non-flammable characteristics.The NiZn batteries are designed to provide reliable, sustainable power for Uninterruptible Power Supply (UPS) systems for data centers and other critical infrastructures. Through the GSLL Facility, the Group will receive funding to further advance the NiZn initiative — supporting progress toward a safer and more sustainable future.Gold Peak views sustainability as a crucial value driver for achieving profitable, long-term growth. In FY24/25, it achieved a 4% year on year reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to FY23/24 baseline year. It remains committed to its interim and long-term reduction targets as follows:- a 20% reduction by 2030 compared to the FY23/24 baseline;- a 60% reduction by 2040; and- the achievement of net-zero operational emissions (i.e., 100% reduction) by 2050.Among many sustainability awards, six of the Group’s battery manufacturing facilities have achieved Zero Waste to Landfill Platinum and Gold validation from UL Solutions, demonstrating its commitment to diverting 95-100% of waste from landfills through effective waste reduction and diversion strategies. Additionally, GP Batteries and GP Energy Tech have gained EcoVadis Bronze medal during FY25/26. The Group is also continuously ramping up the solar panels in factories to realize its decarbonization goals.Regina Lee, Head of Commercial Banking at Hang Seng Bank Limited, said, “This syndicated facility reflects the market’s confidence in Gold Peak’s long-term strategy and sustainability efforts. Hang Seng Bank is honoured to act as sole mandated lead arranger and bookrunner for a green and sustainability-linked loan facility, delivering a structure that incentivises performance against clear sustainability targets and supporting the Group’s continued investment in rechargeable battery manufacturing. Building on our long-standing relationship with Gold Peak, we’ll continue to work closely with the Group to align financing with sustainability outcomes, creating long-term value for stakeholders and the wider community.”The 3-year GSLL Facility features a tiered incentive mechanism that rewards progress toward sustainability targets, with Gold Peak eligible for an interest rate reduction upon achievement. Gold Peak plans to deploy the proceeds to further strengthen its financial position, accelerate the expansion of its rechargeable battery and sustainable energy solutions businesses, support long-term investment in advanced manufacturing technologies, drive operational excellence, and deepen its commitment to green and sustainable business practices.(Center) Brian Li, Vice Chairman and Executive Vice President of Gold Peak, signed the GSLL Facility of HK$675 million with 10 major banks.(7th from the left) Victor Lo, Chairman and Chief Executive of Gold Peak, expressed gratitude to the banks for their continued and unwavering support of the GSLL Facility.Gold Peak Technology Group Limited Charlotte WongSenior Manager, Corporate Communications Tel: (852) 2485 5328Email: charlotte_wong@goldpeak.comAJA Capital LimitedAvy Yu / Janet LouieTel: (852) 9500 4443 / (852) 9155 5615Email:avy.yu@ajacapital.com.hk / janet.louie@ajacapital.com.hkAbout Gold PeakGold Peak Technology Group is a global battery and electronics company with an aspiration to become one of the leaders in providing energy and sound solutions that enlighten and empower lives, and with sustainability as a focus.The parent company, Gold Peak Technology Group Limited (SEHK: 40), was established in 1964 and has been listed on the Stock Exchange of Hong Kong since 1984. Gold Peak holds a majority stake at 86.18%* in the Singapore-listed GP Industries Limited as its major industrial investment vehicle and operates manufacturing, R&D, marketing and distribution operations in more than 10 countries around the world.Gold Peak Technology Group Limited not only develops its consumer batteries, electronics and audio products, but also puts great emphasis on R&D of new rechargeable battery and B2B battery technologies. The Group has built renowned brand names for its major product categories, including GP batteries, GP Recyko batteries, KEF premium audio products and Celestion professional speaker drivers.www.goldpeak.com(* shareholding % as at 11 May 2026) Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com